UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform

Core Insights - Zai Lab Limited (NASDAQ:ZLAB) is recognized as one of the top high-growth Chinese stocks, with UBS initiating coverage with a Buy rating and a price target of $35, highlighting its shift from a China-centric strategy to a global innovation focus [1] - UBS believes Zai Lab is undervalued due to recent disappointments in the Chinese market and that the global pipeline offers significant long-term value that the market has not fully recognized [2] Company Overview - Zai Lab Limited is a commercial-stage biopharmaceutical company operating in China and the United States, dedicated to developing therapies for significant unmet medical needs in oncology, immunology, neuroscience, and infectious diseases [3] Market Trends - The global pipeline indicates a movement towards high-value, innovative treatments that could redefine Zai Lab's development trajectory over the next decade [2]